Century Therapeutics Advances CNTY-813 Development Progress
"We are executing our pipeline with discipline to deliver an iPSC-derived islet replacement therapy to patients. The progress of CNTY-813 highlights what Century can achieve pairing our Allo-Evasion engineering with a scalable iPSC platform," said Brent Pfeiffenberger, Chief Executive Officer of Century Therapeutics. "In a relatively short time since initiating this program, we have advanced CNTY-813 into IND-enabling studies on a timeline we believe is highly competitive with leading efforts in the field. With an IND submission expected in the fourth quarter of 2026 and initial clinical data anticipated in the second half of 2027, our focus is clear: to deliver a differentiated, patient-centric, potentially curative approach for people with type 1 diabetes while continuing to expand our autoimmune disease portfolio with CNTY-308."
Trade with 70% Backtested Accuracy
Analyst Views on IPSC
About IPSC
About the author
Century Therapeutics Q1 Earnings Beat Expectations
- Earnings Beat: Century Therapeutics reported a Q1 GAAP EPS of -$0.11, exceeding expectations by $0.06, indicating an improvement in financial performance that could bolster investor confidence.
- Strong Cash Position: As of March 31, 2026, the company holds $217 million in cash, cash equivalents, and marketable securities, providing a cash runway into Q1 2029, ensuring financial stability for the coming years.
- Revenue Growth: The company generated $109.2 million in revenue for Q1, and although still operating at a loss, the revenue increase suggests rising market demand for its products or services, enhancing future profitability potential.
- Market Ratings: Century Therapeutics ranks favorably among small-cap healthcare stocks according to Seeking Alpha's quant ratings, reflecting optimistic market expectations for its future development and potentially attracting more investor interest.
Century Therapeutics Reports FY 2025 Financial Results
- Financial Overview: Century Therapeutics reported a FY 2025 GAAP EPS of -$0.14 with revenues of $109.2 million, indicating challenges in profitability despite revenue growth.
- Net Loss Comparison: The net loss for FY 2025 was $9.6 million, significantly reduced from $126.6 million in FY 2024, suggesting improvements in cost control and operational efficiency that may lay the groundwork for future profitability.
- Cash Flow Status: As of December 31, 2025, the company's cash, cash equivalents, and marketable securities totaled $117.1 million, a sharp decline from $220.1 million in 2024, reflecting pressure on financial management.
- Operational Support Outlook: The company estimates that its cash and investments as of December 31, 2025, will support operations into Q1 2029, demonstrating confidence in future growth despite cash outflow pressures.
Momentum in iPSC-Derived NK Cells Clinical Trials: 12+ Companies Innovate
- Active Clinical Pipeline: Over 12 companies are currently developing more than 15 iPSC-derived NK cell drugs, indicating robust growth potential in this field, which is expected to drive innovation and market expansion in cancer immunotherapy.
- Key Company Involvement: Major pharmaceutical firms, including Centuary Therapeutics and Fate Therapeutics, are evaluating new drugs aimed at improving treatment outcomes and meeting the increasing market demand, thereby solidifying their market positions.
- Clinical Data Release: Century Therapeutics' CNTY-101 has shown preliminary results in the CARAMEL trial, with initial data expected to be presented on December 5, 2025, indicating potential for treating B-cell-mediated autoimmune diseases, which may attract further investment and attention.
- Strategic Collaboration Agreement: The joint development agreement between ViGenCell and Therabest for TB-420 to treat hepatocellular carcinoma involves a contract fee of 4 billion won (approximately $2.8 million), enhancing the depth of technological collaboration and potentially laying the groundwork for future market expansion.
Why Century Therapeutics (IPSC) Is an Excellent Option for Value Investors
Momentum Investing Overview: Momentum investing contrasts with traditional strategies by focusing on "buying high and selling higher," which can be risky if stocks lose momentum due to overvaluation.
Century Therapeutics, Inc. (IPSC): IPSC is highlighted as a strong candidate for momentum investing, showing a 3.9% price increase in four weeks and a 14.6% gain over 12 weeks, with a favorable Momentum Score of B.
Valuation and Earnings Estimates: IPSC is trading at a low Price-to-Sales ratio of 0.43, indicating it is attractively priced despite its momentum, and has a Zacks Rank #2 (Buy) due to positive earnings estimate revisions.
Quantum Computing Potential: The article also discusses the rapid advancement of quantum computing, with major tech companies integrating it into their infrastructure, and highlights investment opportunities in this emerging field.
Century Therapeutics Appoints New Directors to Accelerate iPSC Therapy Development
- New Board Members: Century Therapeutics has appointed Dr. Han Lee and Dr. Martin Murphy to its Board of Directors, with Dr. Lee joining the Audit and Compensation Committees and Dr. Murphy joining the Compensation and Nominating Committees, aiming to leverage their expertise to advance the company's iPSC-derived therapies towards clinical trials.
- Rich Leadership Experience: Dr. Han Lee, previously President and CFO of ImmPACT Bio, brings extensive capital formation and corporate development experience, which is expected to significantly enhance Century's financial strategy and growth direction.
- Industry Influence: Dr. Martin Murphy has a broad background in life science investment and company creation, having held key positions in several renowned firms, and his addition will strengthen Century's strategic oversight capabilities in the biotechnology sector.
- Accelerating Clinical Progress: CEO Brent Pfeiffenberger stated that the new board members will help expedite the clinical development of iPSC-derived therapies like CNTY-813, aiming to provide potentially curative treatment options for patients with high-impact diseases.
Century Therapeutics Unveils New Beta Islet Initiative for Type 1 Diabetes
Overview of CNTY-813: Century Therapeutics has developed CNTY-813, an iPSC-derived beta islet therapy using Allo-Evasion™ 5.0 technology, aimed at providing durable glucose control for Type 1 diabetes without the need for chronic immunosuppression.
Preclinical Success: Preclinical studies show rapid reversal of diabetes and sustained normoglycemia in diabetic mouse models, with significant insulin secretion and engineered resistance to immune rejection.
Regulatory Timeline: The company plans to initiate IND-enabling studies by the end of 2025, with an IND submission to the FDA anticipated as early as 2026.
Market Potential: With approximately 9 million people affected by Type 1 diabetes globally, this scalable, off-the-shelf therapy could significantly improve patient access and reduce healthcare costs associated with current insulin treatments.
Century Therapeutics Q1 Earnings Beat Expectations
- Earnings Beat: Century Therapeutics reported a Q1 GAAP EPS of -$0.11, exceeding expectations by $0.06, indicating an improvement in financial performance that could bolster investor confidence.
- Strong Cash Position: As of March 31, 2026, the company holds $217 million in cash, cash equivalents, and marketable securities, providing a cash runway into Q1 2029, ensuring financial stability for the coming years.
- Revenue Growth: The company generated $109.2 million in revenue for Q1, and although still operating at a loss, the revenue increase suggests rising market demand for its products or services, enhancing future profitability potential.
- Market Ratings: Century Therapeutics ranks favorably among small-cap healthcare stocks according to Seeking Alpha's quant ratings, reflecting optimistic market expectations for its future development and potentially attracting more investor interest.
Century Therapeutics Reports FY 2025 Financial Results
- Financial Overview: Century Therapeutics reported a FY 2025 GAAP EPS of -$0.14 with revenues of $109.2 million, indicating challenges in profitability despite revenue growth.
- Net Loss Comparison: The net loss for FY 2025 was $9.6 million, significantly reduced from $126.6 million in FY 2024, suggesting improvements in cost control and operational efficiency that may lay the groundwork for future profitability.
- Cash Flow Status: As of December 31, 2025, the company's cash, cash equivalents, and marketable securities totaled $117.1 million, a sharp decline from $220.1 million in 2024, reflecting pressure on financial management.
- Operational Support Outlook: The company estimates that its cash and investments as of December 31, 2025, will support operations into Q1 2029, demonstrating confidence in future growth despite cash outflow pressures.
Momentum in iPSC-Derived NK Cells Clinical Trials: 12+ Companies Innovate
- Active Clinical Pipeline: Over 12 companies are currently developing more than 15 iPSC-derived NK cell drugs, indicating robust growth potential in this field, which is expected to drive innovation and market expansion in cancer immunotherapy.
- Key Company Involvement: Major pharmaceutical firms, including Centuary Therapeutics and Fate Therapeutics, are evaluating new drugs aimed at improving treatment outcomes and meeting the increasing market demand, thereby solidifying their market positions.
- Clinical Data Release: Century Therapeutics' CNTY-101 has shown preliminary results in the CARAMEL trial, with initial data expected to be presented on December 5, 2025, indicating potential for treating B-cell-mediated autoimmune diseases, which may attract further investment and attention.
- Strategic Collaboration Agreement: The joint development agreement between ViGenCell and Therabest for TB-420 to treat hepatocellular carcinoma involves a contract fee of 4 billion won (approximately $2.8 million), enhancing the depth of technological collaboration and potentially laying the groundwork for future market expansion.
Why Century Therapeutics (IPSC) Is an Excellent Option for Value Investors
Momentum Investing Overview: Momentum investing contrasts with traditional strategies by focusing on "buying high and selling higher," which can be risky if stocks lose momentum due to overvaluation.
Century Therapeutics, Inc. (IPSC): IPSC is highlighted as a strong candidate for momentum investing, showing a 3.9% price increase in four weeks and a 14.6% gain over 12 weeks, with a favorable Momentum Score of B.
Valuation and Earnings Estimates: IPSC is trading at a low Price-to-Sales ratio of 0.43, indicating it is attractively priced despite its momentum, and has a Zacks Rank #2 (Buy) due to positive earnings estimate revisions.
Quantum Computing Potential: The article also discusses the rapid advancement of quantum computing, with major tech companies integrating it into their infrastructure, and highlights investment opportunities in this emerging field.
Century Therapeutics Appoints New Directors to Accelerate iPSC Therapy Development
- New Board Members: Century Therapeutics has appointed Dr. Han Lee and Dr. Martin Murphy to its Board of Directors, with Dr. Lee joining the Audit and Compensation Committees and Dr. Murphy joining the Compensation and Nominating Committees, aiming to leverage their expertise to advance the company's iPSC-derived therapies towards clinical trials.
- Rich Leadership Experience: Dr. Han Lee, previously President and CFO of ImmPACT Bio, brings extensive capital formation and corporate development experience, which is expected to significantly enhance Century's financial strategy and growth direction.
- Industry Influence: Dr. Martin Murphy has a broad background in life science investment and company creation, having held key positions in several renowned firms, and his addition will strengthen Century's strategic oversight capabilities in the biotechnology sector.
- Accelerating Clinical Progress: CEO Brent Pfeiffenberger stated that the new board members will help expedite the clinical development of iPSC-derived therapies like CNTY-813, aiming to provide potentially curative treatment options for patients with high-impact diseases.
Century Therapeutics Unveils New Beta Islet Initiative for Type 1 Diabetes
Overview of CNTY-813: Century Therapeutics has developed CNTY-813, an iPSC-derived beta islet therapy using Allo-Evasion™ 5.0 technology, aimed at providing durable glucose control for Type 1 diabetes without the need for chronic immunosuppression.
Preclinical Success: Preclinical studies show rapid reversal of diabetes and sustained normoglycemia in diabetic mouse models, with significant insulin secretion and engineered resistance to immune rejection.
Regulatory Timeline: The company plans to initiate IND-enabling studies by the end of 2025, with an IND submission to the FDA anticipated as early as 2026.
Market Potential: With approximately 9 million people affected by Type 1 diabetes globally, this scalable, off-the-shelf therapy could significantly improve patient access and reduce healthcare costs associated with current insulin treatments.
